Abeona Therapeutics Inc（ABEO）財務資料ABEOAbeona Therapeutics Inc

Evaluating the bottom line, Abeona Therapeutics Inc maintains a gross margin of 63.30%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -119.97%, while the net margin is -177.43%. These profitability ratios, combined with a Return on Equity (ROE) of -43.13%, provide a clear picture of how effectively ABEO converts its operational activities into shareholder value.

In the context of the broader market, ABEO competes directly with industry leaders such as OCGN and AMRN. With a market capitalization of $265.91M, it holds a leading position in the sector. When comparing efficiency, ABEO's gross margin of 63.30% stands against OCGN's 100.00% and AMRN's 35.51%. Such benchmarking helps identify whether Abeona Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Abeona's gross margin is strong at 63.30% for Q2 2026, and it has shown significant revenue growth with $11,380,000 reported for Q2 2026, compared to $400,000 in Q2 2025.